7.2 High-Risk Oral Hazardous Drugs
Key Takeaways
- Methotrexate and tamoxifen are both NIOSH Table 1 hazardous drugs commonly dispensed as oral tablets in retail and specialty pharmacy, making them the primary high-risk oral HDs tested in this domain.
- A drug's NIOSH table status attaches to the drug itself, not to its dose or indication — low-dose, non-oncology methotrexate (e.g., weekly dosing for rheumatoid arthritis) remains NIOSH Table 1.
- Only a facility's documented Assessment of Risk, not an individual technician's judgment, can adjust containment for a specific low-risk dispensing task; the chemo-glove floor from USP <800> still applies regardless.
- Doxorubicin has no oral dosage form — it is administered only by injection as a potent vesicant — so it functions as a severity benchmark in this domain rather than a real oral dispensing scenario.
- An oral tablet's routine appearance never signals that PPE requirements don't apply; chemotherapy-rated gloves are the minimum floor for handling any Table 1 oral hazardous drug.
High-Risk Oral Hazardous Drugs
No needle, no IV bag, no cytotoxic warning sticker on an infusion pump — just a bottle of tablets that looks like every other prescription on the shelf. That is exactly why oral hazardous drugs (HDs) are a heavily tested trap on the PTCB Hazardous Drug Management exam: technicians who would never handle an antineoplastic IV bag without full PPE will sometimes count oral tablets bare-handed, because nothing about the dosage form signals danger. Tablet dust, a chipped coating, or residue transferred from a counting tray can still create real contamination and exposure risk. The exam expects you to recognize specific high-risk oral hazardous drugs by name and apply the correct minimum handling requirement even when the task looks routine.
The Reference Drugs
| Drug | Class | NIOSH Table | Oral Dosage Form? | Key Note |
|---|---|---|---|---|
| Methotrexate | Antineoplastic/antimetabolite; also used as a non-oncology immunosuppressant at low doses | Table 1 | Yes — oral tablets are routinely dispensed | Prescribed at high antineoplastic doses for cancer and at low, non-antineoplastic doses (e.g., weekly, for rheumatoid arthritis or psoriasis). USP <800> permits a facility-specific Assessment of Risk to be considered for these low, non-oncology-dose dispensing tasks — but the drug itself remains NIOSH Table 1 regardless of the prescribed dose or indication |
| Tamoxifen | Antineoplastic/hormonal agent (selective estrogen receptor modulator) | Table 1 | Yes — daily oral tablets, typically for years of continuous therapy | Carries reproductive and developmental toxicity warnings; high, ongoing dispensing volume makes it one of the most frequently handled oral HDs in retail and specialty pharmacy |
| Doxorubicin | Antineoplastic antibiotic (anthracycline) | Table 1 | No — administered only as an IV injectable; no oral doxorubicin dosage form is marketed | Included here as the benchmark drug: a potent vesicant causing severe tissue damage on extravasation. Because it has no oral form, an exam item describing an “oral doxorubicin tablet” is testing whether you catch a route-of-administration mismatch, not a real dispensing scenario |
Why Dose or Indication Doesn't Change NIOSH Status
The most common trap in this section involves methotrexate. A technician sees a prescription for a low weekly dose intended for an autoimmune condition, not cancer, and assumes the drug has somehow stopped being hazardous. It hasn't. NIOSH Table 1 status attaches to the drug itself, not to the dose or the diagnosis it is being used for. What can change is whether a facility's documented Assessment of Risk permits reduced containment for that specific counting/dispensing task — and that determination belongs to the facility's HD program, never to an individual technician's on-the-spot judgment call.
The Minimum Floor Never Disappears
Regardless of what an Assessment of Risk concludes, USP <800> sets chemotherapy-rated gloves (tested to ASTM D6978) as the minimum PPE floor for handling any Table 1 oral hazardous drug — counting, verifying, or dispensing — even when reduced containment is otherwise permitted for the task. Detailed glove and gown selection is covered in the PPE domain of this guide; the takeaway here is narrower and just as testable: “oral” and “tablet” never mean “no PPE required.”
Doxorubicin: The Benchmark, Not a Dispensing Scenario
Doxorubicin appears throughout hazardous-drug training materials as the textbook example of the highest-severity antineoplastic — a vesicant potent enough to destroy tissue if it leaks from a vein during infusion. That severity is exactly why it works as a mental benchmark: it calibrates how seriously to take any Table 1 drug, including the oral ones that do not look dangerous. But doxorubicin itself has no oral dosage form, so it will never appear in a genuine dispensing-counter scenario about counting or splitting tablets. If an exam item describes an oral doxorubicin tablet or capsule, treat that detail as a signal that something in the scenario does not match real pharmacology — not as a cue to recall oral-handling rules for a drug that is not given by mouth.
Realistic Scenario
A new technician is handed a prescription for tamoxifen 20 mg, quantity 30. A colleague reaches for the shared counting tray and spatula used for every other prescription that shift, planning to count the tablets bare-handed because “it's just a tablet, not chemo in a bag.” Later that same day, a second prescription arrives: methotrexate 2.5 mg tablets, “take 4 tablets once weekly,” for a patient with rheumatoid arthritis. A different technician assumes that because the dose is low and the indication is not cancer, this bottle does not need the same precautions as the oncology stock bottle of methotrexate kept in the same pharmacy. Both technicians are making the same underlying error: treating an oral tablet's routine appearance, or a low dose and non-oncology indication, as proof that NIOSH Table 1 handling requirements do not apply. The correct response in both cases is identical — confirm the drug's NIOSH table status from the current list, apply the facility's Assessment of Risk determination for that specific task if one exists, and, at minimum, put on chemotherapy-rated gloves before touching the tablets, regardless of dose, indication, or how many times that same prescription has been filled before.
Which of the following is a true statement about doxorubicin as tested on the PTCB Hazardous Drug Management exam?
A prescription for low-dose oral methotrexate (2.5 mg tablets, weekly dosing) for rheumatoid arthritis arrives at the pharmacy. Which statement correctly reflects its NIOSH/USP <800> status?
What minimum PPE does USP <800> require for counting and dispensing whole tamoxifen tablets, even if a facility's Assessment of Risk permits reduced containment for the task?
Why do tamoxifen and methotrexate appear so frequently in the dispensing domain of this exam, compared with a drug like doxorubicin?